Need Help?
Your request has been submitted.
We will contact you shortly.
We were unable to process your request.
Please try again after sometime.
Contact Support
Need Help?
Your request has been submitted.
We will contact you shortly.
We were unable to process your request.
Please try again after sometime.
An Innovative Micronized Abiraterone Acetate
62:00
Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Chapter 1 08:56
YONSA®(first and onlymicronized abiraterone acetate) for mCRPC
Chapter 2 06:31
Benefits of a Micronized Formulation
Chapter 3 25:01
Improving Survival and Etending Time with YONSA®
Chapter 4 12:56
YONSA SUPPORTTM Programs®
Chapter 5 06:45This webinar outlines the benefits of YONSA, the first and only micronized formulation of abiraterone acetate for mCRPC. Some benefits including increased absorption and eliminating food restrictions are discussed in detail.
Board Certified Urologist
Director of Clinical Research
Dr. Christopher Pieczonka graduated from the SUNY Buffalo School of Medicine in 1997. He then completed his surgical and urologic training at SUNY at Buffalo Consortium Program in 2003. He is board certified by the American Board of Urology and is an active member of the American Urological Association. Dr. Pieczonka also has been co-author of over 30 peer reviewed publications and is the director of clinical research at Associated Medical Professionals PLLC.
This promotional, non-CME program presented on behalf of Sun Pharma is intended only for US healthcare professionals involved in the treatment of adult patients with metastatic castration-resistant prostate cancer.